Article Sidebar

PDF
Date Published: 07/08/2021
Abstract Views: 485
Views PDF: 190
DOI: https://doi.org/10.51298/vmj.v504i1.870
Issue
Vol. 504 No. 1 (2021)
Section
Các bài báo
How to Cite
Bích Ngọc, T. ., Gia Tuyển, Đỗ ., & Gia Bình, N. . (2021). THE OUTCOME OF CONCURRENT TREATMENT WITH 6-MONTH HIGH DOSE INTRAVENOUS ENDOXAN AND PLASMA EXCHANGE FOR LUPUS NEPHRITIS FLARE IN NEPHRO-UROLOGY DEPARTMENT, BACH MAI HOSPITAL. Vietnam Medical Journal, 504(1). https://doi.org/10.51298/vmj.v504i1.870

THE OUTCOME OF CONCURRENT TREATMENT WITH 6-MONTH HIGH DOSE INTRAVENOUS ENDOXAN AND PLASMA EXCHANGE FOR LUPUS NEPHRITIS FLARE IN NEPHRO-UROLOGY DEPARTMENT, BACH MAI HOSPITAL

Trần Bích Ngọc1,, Đỗ Gia Tuyển1,2, Nguyễn Gia Bình3
1 Urology-Nephrology and Dialysis Center, Bach Mai Hospital
2 Hanoi Medical University
3 Bach Mai Hospital

Main Article Content

Abstract

Objectives: evaluate the change in clinical, laboratory in patients with lupus nephritis flare to concurrent treatment with plasma exchange and high dose intravenous endoxan. Participants: 55 patients with lupus nephritis flare were given treatment from October 2014 to June 2018 in Bach mai Hospital. The standard regimen includes 3 sessions of plasma exchange, followed by monthly intravenous endoxan (500mg/m2 BSA) for 6 months in combination with prolonged steroid. Methods: prospective study Outcomes: After 6 months, mean SLEDAI score decreased from 24.1±5.5 to 11.5±6.1 (p < 0.00001). Serum anti ds-DNA antibodies level decreased from 163.9±131.8 IU/mL to 75.3±76.1 IU/mL (p =0.005). Mean eGFR increased from 27.6±20.6 to 67.6±37.7 ml/min/1.73m2. Complete renal response was 10.9%, partial renal response 49.1%. Conclusions: This treatment was efficient, safe and could be appropriate to apply in Vietnam.

Article Details

Keywords

lupus nephritis, plasma exchange, cyclosphosphamid

References

1. Liệu, Đ.T., Nghiên cứu đối chiếu lâm sàng và mô bệnh học ở bệnh nhân viêm thận do bệnh lupus ban đỏ hệ thống. 2001, Học viện Quân Y: Hà Nội.
2. chairat Shayakul, L.O.-a.-y., Phisit Chirawong, et all, Lupus nephritis in Thailan: Clinicopathologic Findings and Outcome in 569 patients. American Journal of Kidney Diseases, 1995. 26(2): p. 300-307.
3. Fanouriakis A, e.a., 2019 Update of the joint European League Aagainst Rheumatism and European Renal Association- European Dialysis and Tranplant Association (EULAR/ERA/EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis, 2020. 79: p. 713-723.
4. Pagnoux, c., Plasma exchange for lupus erythematosus. Transfus Apher Sci, 2007. 36: p. 187-193.
5. Zihong Liu, H.Z.e.a., Multitarget Therapy for Induction Treatment of Lupus Nephritis. A Randomized, Controlled Trial. Ann Intern Med. doi:10.7326/M14-1030, 2014.
6. Lewis EJ, H.L., Lan SP, Rohde RD, Lachin JM., A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med., 1992. 326: p. 1373-9.
7. Leyla Gadakchi, e.a., Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis. Iranian Journal of Kidney Diseases, 2018. Volume 12(5): p. 288-92.
8. Ramaswamy Subramanian, H.P., Vinod Ravindra, Safey of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases.Indian Journal of Rheumatology, 2019. 14: p. 127-35.